

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/010002
	Serial No.	Not Yet Assigned
	Applicant	LUYTEN et al.
	Filing Date	January 30, 2006
	Group	Not Yet Assigned
	IDS Filed	January 30, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,786,217	07/28/98	Tubo et al.			
	6,410,268	06/25/02	Ni et al.			
	6,413,511	07/02/02	Glorioso et al.			
	US 2002/0123483	09/05/02	Saxena et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 1 312 614 A1	05/21/03	EPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	International Preliminary Report on Patentability (PCT/BE2004/000117) (mailed 5 December, 2005).					
	International Search Report (PCT/BE2004/000117) (mailed 2 February, 2005).					
	Response to the Written Opinion (PCT/BE2004/000117) (mailed 1 June, 2005).					
	Written Opinion of the International Searching Authority (PCT/BE2004/000117) (mailed 2 February, 2005).					
	Wuyts et al., "The CXC Chemokine GCP-2/CXCL6 is Predominantly Induced in Mesenchymal Cells by Interleukin-1 β and is Down-Regulated by Interferon- γ : Comparison with Interleukin-8/CXCL8," <i>Lab. Invest.</i> 83:23-34 (2003).					
EXAMINER			/Bridget E. Bunner/			
DATE CONSIDERED			01/28/2008			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						